BLOG
Blog
Forging a Path Forward for Substance Abuse Potential Studies With the Cross-Company Abuse Liability Council By Beatrice Setnik, PhD
Beatrice Setnik, PhD, discusses the mission of CCALC, the importance of abuse potential studies, and challenges in evaluating psychedelics for clinical use.
Blog
Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development
Discover FDA guidances for oligonucleotide bioanalysis, safety assessments, and clinical pharmacology, and how Altasciences supports regulatory-compliant drug development.
Blog
Guest Blog: Reflecting on the 2024 Society of Toxicology of Canada Symposium, by Ria Falvo, Director, Reporting
Ria Falvo, Director of Reporting and STC Committee Member, reflects on the STC’s legacy following her attendance at the 56th Annual STC Symposium.
Blog
Highlights From the 2024 American College of Toxicology 45th Annual Meeting
Dr. Francesca Barone, Site Director, Altasciences, recounts highlights and notable presentations from the 2024 American College of Toxicology 45th Annual Meeting.
Blog
Case Study: How Altasciences Launched a Phase I Study 70% Faster Than the Industry Standard
Discover how Altasciences reduced clinical trial start-up timelines by 70%, initiating the first dose of a Phase I MAD study in just 3.5 weeks.